Recent Scientific Developments in Autoimmune Hematological Disorders

Dear Colleagues,

Autoimmune hematological disorders (AHDs) could be primary, so-called idiopathic, or secondary to other conditions, such as malignancies, lymphoproliferative disorders, viral infections, and drug treatment. Usually, they are caused by autoantibodies that recognize antigens located on the blood components, leading to their destruction. They may involve a single blood cell lineage or multiple. However, the reasons why these autoantibodies are produced are still unclear. They may depend on the modification of endogenous antigens, molecular mimicry of microbial antigens, or a reduced suppression of self-reactive lymphocytes. At present, numerous therapeutic options are available to treat those disorders; nevertheless, no treatment is resolutive. Recently, several authors have also reported that AHDs could follow coronavirus disease 2019 (COVID-19). Because of the high number of people affected by SARS-CoV-2, the need for scientific literature in this field is urgent to close the gap in our knowledge on AHDs. Last but not the least, there is no evidence on post-mortem diagnosis of AHDs, and it appears to be almost impossible if clinical data are not available.   

This Special Issue focuses on the recent scientific developments that may help to deepen our knowledge of AHDs. Submissions of scientific papers (original articles, systematic reviews, short communications, and other works) on related topics are welcome and encouraged.

Prof. Dr. Aniello Maiese
Dr. Alice Chiara Manetti
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Medicina is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• autoimmune
• hematology
• diagnosis
• treatment
• novelty
• post-mortem